Diagnostic Criteria and Considerations for Multiple Sclerosis

Clinical Features and Diagnostic Reasoning

The patient's history of recurrent neurological episodes with spontaneous recovery, along with MRI findings of multifocal T2 hyperintense lesions in characteristic locations, supports a diagnosis of relapsing-remitting multiple sclerosis, as suggested by the American Academy of Neurology 1, 2
Dissemination in time, demonstrated by the patient experiencing neurological symptoms last year that resolved spontaneously, followed by new symptoms this year, is a key feature of multiple sclerosis, according to the National Multiple Sclerosis Society 3
The relapsing-remitting pattern, characterized by spontaneous recovery from the first episode followed by new symptoms, is consistent with relapsing-remitting MS rather than a progressive course, as outlined by the European Committee for Treatment and Research in Multiple Sclerosis 1, 2

T2 hyperintense foci in multiple characteristic locations, including periventricular, infratentorial, and juxtacortical areas, strongly support an MS diagnosis, as stated by the International Society for Magnetic Resonance in Medicine 1, 2, 4
Periventricular involvement, with three or more periventricular lesions, is highly specific for MS, according to the McDonald Criteria 5, 3
Infratentorial lesions, such as those in the pons, are one of the four key anatomical regions for demonstrating dissemination in space, as defined by the National Institute of Neurological Disorders and Stroke 4, 3

Neuromyelitis optica spectrum disorder (NMOSD) should be excluded through AQP4-IgG antibody testing, as it can present with similar relapsing symptoms but requires different treatment, as recommended by the Neuromyelitis Optica Study Group 8
MOG-antibody disease should be considered and tested for, as it can present with optic neuritis, myelitis, and brainstem encephalitis, and has distinct treatment implications, according to the MOG Consortium 8
Acute disseminated encephalomyelitis (ADEM) is typically monophasic with large, confluent lesions, and is more common in children, as described by the Pediatric Multiple Sclerosis Study Group 5, 3

A complete spinal cord MRI, including cervical and thoracic regions, is essential to evaluate for asymptomatic cord lesions, which can strengthen the diagnosis, as recommended by the Consortium of Multiple Sclerosis Centers 7
Lumbar puncture for CSF analysis, including oligoclonal bands and elevated IgG index, provides supportive evidence for MS, particularly if MRI criteria are borderline, according to the National Multiple Sclerosis Society 7
Anti-aquaporin-4 (AQP4) antibody testing is crucial to exclude NMOSD, which requires different treatment and can be worsened by MS therapies, as stated by the International Panel on Diagnosis of Multiple Sclerosis 8, 7

Early initiation of high-efficacy disease-modifying therapy is recommended to improve long-term outcomes in MS, but only after excluding mimics, as suggested by the European Committee for Treatment and Research in Multiple Sclerosis 7
MS-specific therapy should not be started until NMOSD and MOG-antibody disease are definitively excluded, as some MS therapies can worsen these conditions, according to the National Institute of Neurological Disorders and Stroke 8, 7
Diagnostic pitfalls to avoid include diagnosing MS based solely on MRI findings without clinical correlation, assuming all white matter lesions are demyelinating, and skipping antibody testing for AQP4 and MOG, as outlined by the American Academy of Neurology 7, 1, 4